Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis / Baroncini, Damiano; Simone, Marta; Iaffaldano, Pietro; Brescia Morra, Vincenzo; Lanzillo, Roberta; Filippi, Massimo; Romeo, Marzia; Patti, Francesco; Chisari, Clara Grazia; Cocco, Eleonora; Fenu, Giuseppe; Salemi, Giuseppe; Ragonese, Paolo; Inglese, Matilde; Cellerino, Maria; Margari, Lucia; Comi, Giancarlo; Zaffaroni, Mauro; Ghezzi, Angelo. - In: JAMA NEUROLOGY. - ISSN 2168-6157. - 78:6(2021), pp. 726-735. [10.1001/jamaneurol.2021.1008]
Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
Brescia Morra, Vincenzo;Lanzillo, Roberta;
2021
Abstract
Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging.| File | Dimensione | Formato | |
|---|---|---|---|
|
jamaneurology_baroncini_2021_oi_210019_1622672547.60916.pdf
solo utenti autorizzati
Licenza:
Accesso privato/ristretto
Dimensione
604.91 kB
Formato
Adobe PDF
|
604.91 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
